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Abstract
W e evaluated whether FLAVORx helped th irty  Thai children take opened capsule, crushed tablets 
and liquid generic ARVs w ith more ease. A ll children had excellent adherence, evaluated by PACTG 
Standard International Questionnaire and interviewing, before and after one month o f FLAVORx. 
Eighty percent to o k  ARV w ith more ease and wish to  continue FLAVORx. Strawberry was the 
most popular flavor.
Background
M ost children w ith HIV infection live in  resource-limited 
settings. W ith the recent availability o f generic antiretrovi­
rals (ARV), m ore children are being treated. The Thai Gov­
ernm ent Pharmaceutical O rganization (GPO) began 
producing generic ARVs in  2001. O ut o f about fifty thou ­
sand children living w ith HIV in  Thailand, five thousand 
children are now  on  ARVs [1]. However, the form ulations 
o f ARVs produced by the GPO are m ainly solid dosage 
forms for adults w ith only a few liquid dosage forms suit­
able for children. In addition, the Access to  Care Program 
by the Thai G overnm ent provides m ainly pill form ula­
tion. C hildren under seven years o f age are usually unable 
to  swallow pills, capsules or tablets. The HIV N etherlands 
Australia Thailand Research C ollaboration (HIV-NAT), 
Thai Red Cross AIDS Research Centre, has over one h u n ­
dred fifty children on  ARVs, m any o f these children have
to take opened capsule, crushed tablets or large am ounts 
o f  liquid  ARVs. Inappropriate form ulations and bad  taste 
have been reported to lead to  poor adherence in  children 
[2] w hich can in  tu rn  cause treatm ent failure [3-6]. We 
th ink  tha t it is im portan t to explore ways to  m ake it easier 
for our children to  take ARVs since these are long term  
chronic m edications tha t children w ith HIV m ust take to 
survive; anything th a t can be done to  m ake their circum­
stances easier, live happier is a virtue.
FLAVORx flavors are FDA, TGA (Australian Regulatory 
Agency -  Therapeutic Goods A dm inistration), HAS 
(Health Services Australia) and  Health Canada approved. 
W hen FLAVORx was added in  the proper form ulations 
they m ask the bad, bitter or acrid tastes o f m edications. 
FLAVORx has been used in  the U nited States, Canada, 
Australia and  New Zealand to  make m edicine including
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ARVs m ore palatable. FLAVORx is a n o n  allergenic, sugar- 
free inert product [see m ore inform ation in  additional file 
1, 2] tha t does n o t interfere w ith drug levels. Over forty 
m illion  prescriptions were filled so far w ith FLAVORx, 
w ithout any interactions reported. (Personnel com m uni­
cation: Kenny Kramm, President, CEO o f FLAVORx com ­
pany). Im pact o f  FLAVORx o n  pediatric inpatients 
adm itted to  a Children's hospital has been evaluated as 
reported earlier [7,8]. In this study, we evaluated w hether 
FLAVORx, a taste m asking blend, helped thirty Thai chil­
dren take opened capsule, crushed tablet and liquid 
generic ARVs w ith m ore ease.
Patients and methods
From Septem ber to N ovem ber 2005, caregivers o f chil­
dren w ith HIV infection w hom  were part o f  our prospec­
tive cohort study and  taking opened capsule, crushed 
tablets or liquid  ARVs were asked if  they were interested in  
having their children use a taste-masking product. The 
first thirty children w hom  caregivers agreed were 
recruited. All caregivers understood  the study and  signed 
the inform ed consent form. The study protocol, HIV-NAT 
015, opened label, one arm, cohort study, was approved 
by the Chulalongkorn Institutional Review Board.
Before the start o f the study, ten flavors (strawberry, 
orange, banana, grapes, bubble gum, water m elon, 
lem on, cherry, vanilla, chocolate) were mixed w ith the 
following generic ARVs, products o f Thai GPO, by 
research staffs at The FLAVORx Research Institute and 
taste to find the best flavors for taste masking: Stavudine 
or d4T (Stavir®, GPO) opened capsule, Z idovudine or AZT 
(Antivir®, GPO) opened capsule and liquid, D idanosine 
or ddI (Divir®, GPO) powder, Nevirapine or NVP (Nera- 
vir®, GPO) crushed tablet, Lamivudine or 3TC (Lamivir®, 
GPO) crushed tablet and liquid, or Efavirenz or EFV (Sto- 
crin®, Merck) opened capsule and  Indinavir or IDV (Crix­
ivan®, Merck) opened capsule supported by the National 
Access to  Antiretroviral Program for People living w ith 
HIV/AIDS (NAPHA), were also tested. There were ten 
available flavors. The best flavors were then  m ixed w ith 
each ARV, tasted and  scored by at least two Thai physi­
cians and six nurses to  determ ine the m ost likely popular 
flavors to Asians' palate. The best three flavors for each 
ARV were then  offered to  the children in  the study before 
the o ther flavors were offered in  order to lim it the num ber 
o f flavors children have to taste.
C hildren were followed twice, one m o n th  apart. At each 
visit, the caregivers were asked to  com plete the approved 
Thai version o f the NIAID Pediatric AIDS Clinical Trial 
Group (PACTG) Standard International Q uestionnaire 
[9]. The caregivers were also interviewed using open 
ended questions abou t the child's adherence and  diffi­
culty in  taking ARV, the caregiver's technique o f giving
ARV to the child and  their attitude towards using a taste- 
m asking product. At the first visit, children were encour­
aged to  taste the different flavors and  choose up  to  three 
flavors themselves. They can use different selected flavors 
w ith each o f their m edications. The study nurse instructed 
the caregiver on  mixing procedure w hich were different 
for each child depending on  the form ulation and  dosing 
o f  ARV. For example, one to  three drops o f FLAVORx plus 
four drops o f a sweetening agent were used to mix one 
crushed tablet or one opened capsule in  five m l o f water. 
For the first ten children w hom  caregivers agreed, trough 
levels o f NNRTI or PI were perform ed at b o th  visits. Sam­
ples were draw n just prior to  the next dose for trough lev­
els o f NNRTI or PI at b o th  visits. After using FLAVORx for 
three days, the study nurse called the caregivers to  confirm 
the m ethod  o f m ixing FLAVORx.
Statistic analysis
Statistical analysis was perform ed w ith SPSS version 12.0 
(SPSS, Chicago).
Results
Thirty children were included. The characteristics are 
show n in  Table 1. M ean age was 5.2 ± SD 1.9 years w ith 
forty percent boys. M ost had  m ild  or m oderate HIV symp­
tom s, CDC category [10] A: B: C was 10:12:8. The m edian 
CD4 was 25% (IQR 17-30). M ean weight was 16.2 ± 4.1 
kilograms. M ean height was 102.8 ± 10.9 centimeters. All 
children were using generic NRTIs; m ost com bining w ith 
generic NVP, branded EFV or Kaletra. The caretakers were 
fourteen m others, five fathers, six grandm others and  five 
aunts.
At the first visit, all thirty caregivers answered th a t the 
child had  never m issed any ARV dose and tha t they did 
n o t experience problem s with giving the child the ARV on 
tim e everyday. However, during the interview, m ost car­
egivers reported tha t the child disliked taking ARVs 
because o f  the bitter taste especially generic AZT syrup, 
3TC syrup, ddI powder, NVP crushed tablet and  EFV 
opened capsule. The techniques caregivers used varied 
from  using alarm clock, having the child drink fruit juice 
im m ediately after the dose, mixing ARV w ith syrup, honey 
or food, forcing the child to  take ARV and bribe the child 
w ith treats. The flavors chosen at the first visit were straw­
berry, orange and  grape in  twenty three, fifteen and  four 
children respectively.
At the final visit, caregivers gave the same answers for the 
PACTG adherence questionnaire w ith no  reported p rob­
lems or occurrence o f poor adherence. From the interview, 
twenty four caregivers reported that, after using FLAVORx, 
their children had  an easier tim e taking ARV FLAVORx. All 
o f  them  reported tha t their children liked the nice flavor 
o f  FLAVORx and seven o f twenty four children said the
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T a b le  1: D em ographic D a ta  and Results
N o. gender A ge (y) W t  (Kg) H t  (cm ) C DC CD4% (c e ll/m m 3) R eg im en* Chosen flavors N N R T I T ro u gh  level ** (m g /L ) Reason o f d iscon tinue  FLA V O R x
V is itI V is it II V is itI V is itII
1 F 6.7 16 112.5 B I3%(277) A Z T  Icap+7 mlX2 3TC I/2 tabX2 N V P  3/4 tabX2 S x 3.94 4.I9 Spicy taste
2 M 5.5 17 111 B 39%(II 08) AZT I cap +6 mlX2 3TC 7 mlX2 N V P  3/4 tabX2 S, O x I4.80 7.0I Child prefer to  mix ARV with water
3 F 3.5 12.5 92.5 A 7%(342) 3TC 5 mlX2 EFV 200 mg d4T  I/3 tabx2 O x I I.88 8.29 Spicy taste
4 F 4.2 14 97 A I0%(210) A Z T  I cap +5 mlx2 3TC  6 mlx2 EFV 200 mg S S 2.I4 I.55
5 M 4.8 17.2 106 A 24%(II22) A Z T I cap +7 mlX2 3TC I tab X2 N VP 3/4 tabX2 S, O S,G 5.66 5.60
6 M 5.3 12.5 93 B 6%(459) A Z T  I cap +4 mlX2 3TC 5 mlx2 N V P  I/2 tabx2 S S 3.05 3.45
7 F 4.5 14 99 C I7%(356) A Z T  I cap +5 mlX2 ddI(I70 mg) I x I S,O,G G - -
8 M 4 15 96 A 42%(2278) A Z T  I cap +5 ml 3TC  6 mlx2 EFV 200 mg S x I.93 2.45 Vomiting
9 F 7.5 29.6 126 A 29%(6I4) AZT 2 cap X2 3TC I tab X2 EFV 350 mg S x - - Child prefer to  mix ARV with water
10 M 4.1 15 99 C 22%(945) A Z T I cap +5 mlX2 3TC  7 mlX2 EFV 250 mg S,O S 3.I8 0.00 Repeat ***
1 1 F 4.6 23 106 A 25%(I224) 3TC I tab x2 EFV 300 mg dd I(I I5) 2 x I S S I.40 3.78
12 M 11.5 84.5 C 38%(I732) 3TC  4 mlx2 N V P  I/2 tab X2 d4T  I0 mgx2 O S,G,B 3.5I 4.30
13 F 4.8 14.1 97 A 35%(I428) A Z T  I cap +5 mlX2 3TC  I tabX2 EFV 250 mg S S,B
14 F 2 10.2 83 B 24%(76I) AZT I cap +2 ml x 2 3TC 5 ml x 2 K a le tra  I.4 ml x 2 O S
15 F 4.7 11.6 93 B I5%(250) 3TC  6 mlX2 N V P  I/2 tabX2 d4T  I5 mgx2 S S
16 M 4 13.9 95.5 C 24%(960) A Z T  I cap +4 mlx2 3TC 6 mlx2 EFV 200 mg S S
17 F 5.5 14 104 B 22%(59I) A Z T  I cap +4 mlX2 3TC  I/2 tab x2 N VP 3/4 tabx2 S S
18 M 4.3 15.1 103 C 26%(I26I) A Z T  I cap +5 mlX2 3TC 7 mlX2 EFV 200 mg S S
19 M 7.7 17.5 105 B 23%(9I5) 3TC I/2 tabX2 EFV 250 mg d4T I5 mgX2 O,G G
20 F 5.4 20 105.5 B 4 I% (II 37) A Z T  I cap +5 mlX2 3TC ItabX2 EFV 250 mg S,O B,A
21 F 9.8 18 119 B 27%(I086) A Z T  I cap +8 mlX2 3TC I tabX2 EFV 300 mg O,G G
22 F 8.8 18 116.5 B 6% (II2) A Z T  I cap +8 mlX2 3TC I/2 tabX2 NVP 3/4 tabX2 S G
23 F 1.8 10 82 A 33%(I933) AZT I cap + I mlx2 3TC 5 mlX2 K a le tra  I.4 ml x 2 S,O O
24 M 8 22.6 119 B 25%(809) 3TC I tabX2 d4T I/2 tabx2 N V P  3/4 tab x2 S,O x Child prefer to  mix ARV with water
25 F 4 15.2 94 B 28%(8I7) 3TC I/2 tabX2 EFV 200 mg d4T I5 mg S,B S,B
26 F 6.3 16.9 109 C 26%(723) A Z T  I cap +5 mlX2 3TC I/2 tabX2 NVP 3/4 tabX2 O O
27 F 6.7 18.3 110 C 40%(II 09) 3TC 7 mlX2 EFV 250 mg d4T I5 mg S,O B
28 M 4.5 15 102.5 A 28%(I076) 3TC I/2 tabX2 EFV 200 mg d4T  I5 mgX2 G G
29 F 6 19.2 110 A I2%(551 ) A Z T  I cap +8 mlX2 3TC I/2 tab X2 NVP 3/4 tabX2 S,O G
30 M 5.7 20 114 C I7%(345) A Z T  I cap +8 mlX2 3TC I tabX2 EFV 300 mg S S
*  The bolded drugs w ere mixed w ith  FLAVORx
* *  compare to  N N R TI target serum level: fo r NVP is 3.4 mg/l, EFV is 1.0 mg/l (Ref: John G. Bartlett, John Hopkins University School o f Medicine, Pocket Guide to  adult HIV/AIDS treatm ent, Jan 2005.
* * *  Repeat trough level w ith o u t using FLAVORx = 3.74 mg/l
Chosen Taste: S = straw berry, O  = orange, G = grape, B = banana, A  = apple, X  = children o r  parent did no t w ant to  continue FLAVORx 
Cap = capsule, tab = tab le t
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m edications tasted sweeter. Twenty-four o f thirty (eighty 
percent) children said tha t they liked FLAVORx and 
w anted to  continue using it. Fifteen children (fifty per­
cent) chose to  use the same flavor; strawberry (thirteen), 
orange (two), grapes (four), banana (one), and nine 
w anted to  try new flavors; strawberry (six), orange (ten). 
Six children w ho d idn 't w ant to  continue using FLAVORx; 
caregivers o f  three children found it too  difficult, two chil­
dren (on  orange and strawberry flavors) reported burning 
sensation on  the tongue, and  one child had  repeated vom ­
iting im m ediately after taking FLAVORx (strawberry fla­
vor).
Therapeutic drug m onitoring in  the first ten  children 
showed trough levels above the target serum levels [11] at 
the first and final visits in  all except one boy w ho had 
undetectable level a t the final visit. This boy was taking 
EFV w ith strawberry and  orange flavors. The m other 
reported excellent adherence and  m ore ease o f taking ARV 
after using FLAVORx. Repeat trough level in  this child was 
3.74 mg/l; however, he was n o t taking FLAVORx at that 
time.
Discussion
In eighty percent o f children participants, FLAVORx 
helped them  take ARVs w ith m ore ease by m asking the 
b itter taste o f ARV. Strawberry, orange and  Grape flavors 
were the m ost popular. FLAVORx did  no t affect adherence 
as full adherence was reported in  all children despite the 
problem  o f bitter ARV. In o ther parts o f the world, chil­
dren m ay n o t be as willing to  take bitter ARV. FLAVORx 
did n o t affect ARV trough levels in  n ine o f ten  children.
The using o f taste m asking products has been show n to 
help children take m edications. Robert W ood Johnson 
Children's Hospital in  New Jersey found im provem ent in  
hospitalized children's willingness to  take m edications 
[7,8]. In the U nited States, the m ost popular flavor is b u b ­
ble gum. This was n o t selected by any o f  our patients. Pal­
atable tastes are probably affected by the typical food 
flavors in  each country. This is the first study o f FLAVORx 
in  Asian children. It is likely tha t children from  other 
Asian countries w ould prefer the same flavors as our chil­
dren.
After using FLAVORx, m ost caregivers reported tha t their 
children were happier during m edication taking tim e 
w hich fulfilled our goal for perform ing this study. A few 
caregivers found the mixing procedure too difficult. 
Therefore, this product m ay n o t be ideal to  use in  children 
o f caregivers w ho are unable to  follow mixing procedures. 
Although we canno t be certain, we suspect tha t the child 
w ith undetectable efavirenz level at the final visit did no t 
take his m edication. As an  inert product, FLAVORx should 
n o t effect on  drug levels and  it did n o t in  nine o f ten chil­
dren. Any interaction w ould have also unlikely to  cause an 
undetectable level.
There were two children (on  orange and  strawberry fla­
vors) felt a burn ing  sensation on  the tongue, w hich may 
be due to  excess use o f flavoring agent or used w rong com ­
b ination  o f flavors for tha t child 's sense o f taste. There was 
one child had  repeated vom iting im m ediately after taking 
FLAVORx (strawberry flavor) w hich could be due to  the 
child 's sense o f taste d id  n o t agree w ith this flavor choice 
or the flavoring needed to be adjusted or the child had a 
concom itant illness. After the study, we found tha t at 
tim es some children w ent back to  using the m arketed 
highly concentrated sugar syrup called Hale's Blueboy to 
sweeten the m edications. This is m uch sweeter th an  FLA- 
VORx b u t the high sugar content is n o t good for their den­
tal health.
In summary, m asking the taste o f ARV by using FLAVORx 
helped Thai children take ARV w ith m ore ease. This may 
be explored in  o ther countries especially where adult ARV 
form ulations are used in  children.
Additional m aterial
Additional file 1
Product specific sheet code number 710-381. FLAVORx Strawberry 
Cream Flavor. Flavoring nomenclature: N& A Strawberry Cream Flavor. 
Non-Flavoring Ingredients: Propylene Glycol, Ethyl Alcohol, Water, 
Triacetin. N o allergen, pH: N /A , colorless to pale red, water solubility, no 
alcohol range by volume, recommended storage 7.2- 26 .7°C , absent col- 
iform count.
Click here for file
[http://w ww.biom edcentral.com /content/supplem entary/1742-
6405-3-30-S1.pdf]
Additional file 2
Product specific sheet code number 711-218. FLAVORx Orange Cream- 
sicle Flavor. Flavoring nomenclature: N& A Orange Creamsicle Type Fla­
vor. Non-Flavoring Ingredients: Propylene Glycol, Ethyl Alcohol. No 
allergen, pH: N /A , yellow-green color, water solubility, no alcohol range 
by volume, recommended storage 7.2- 26 .7°C , absent coliform count. 
Click here for file
[http://w ww.biom edcentral.com /content/supplem entary/1742-
6405-3-30-S2.pdf]
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